Latest Biotech News

Eli Lilly expanded its GLP-2 strategy through a licensing deal with Hanmi Pharm for sonefpeglutide, a long-acting GLP-2 analog being developed in short bowel syndrome (SBS). Lilly will pay $75...

A research team led by Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) unveiled an improved CRISPR-Cas9 strategy aimed at increasing precision and safety in human...

Servier agreed to acquire Edgewise Therapeutics’ muscular dystrophy assets in a transaction worth up to $2.65 billion, centered on sevasemten. The deal includes a $1.55 billion upfront payment...

Researchers presented an AI-driven spatial biomarker, ST-DoxPCa, designed to predict which patients with metastatic hormone-sensitive prostate cancer may benefit from adding docetaxel to androgen...

Pfizer and Innovent Biologics announced a back-heavy cancer collaboration involving 12 antibody-based therapies, combining Pfizer’s funding and Innovent’s contributed assets across oncology...

Agios signed an exclusive global licensing deal for Oscotec’s cevidoplenib, a next-generation SYK inhibitor being developed for immune thrombocytopenia (ITP), despite Oscotec’s Phase 2 failure to...

Replimune said it will resubmit its biologics license application for RP1 for advanced melanoma as an urgent matter, aiming to return the therapy to the FDA review queue for a third time. The move...

Revolution Medicines presented expanded Phase 3 results for daraxonrasib at ASCO, showing markedly longer survival versus standard chemotherapy in metastatic pancreatic cancer driven by KRAS G12...

Servier agreed to acquire Edgewise Therapeutics’ muscular dystrophy business for $1.55 billion upfront, with total consideration up to $2.65 billion including potential milestones. The deal gives...

Revolution Medicines reported expanded ASCO data for daraxonrasib in second-line metastatic pancreatic cancer, highlighting a survival benefit in patients with KRAS/ RAS G12 mutations and in the...

Akeso’s ivonescimab, a PD-1/VEGF bispecific, reduced the risk of death by 34% versus a PD-1 inhibitor–chemotherapy comparator in a Phase 3 study in China for previously untreated advanced squamous...

Autobahn Therapeutics said the FDA granted Fast Track status to elunetirom (ABX-002), an investigational oral small molecule prodrug designed to activate CNS thyroid hormone receptors as an...

Rallybio agreed to merge with Avenzo Therapeutics in a new reverse merger after a previous Candid Therapeutics deal was derailed by UCB’s $2 billion buyout. Under the agreement, Avenzo...

A report on China’s new cell and gene therapy (CGT) rules says the regulatory update could change how developers structure trials, manufacturing, and commercial planning for CGT products in the...

Eli Lilly licensed Hanmi Pharma’s long-acting GLP-2 agonist sonefpeglutide for short bowel syndrome, paying $75 million upfront with up to $1.185 billion more tied to clinical, regulatory, and...

Interim data from SWOG S1823/GCC suggest microRNA-371a-3p (miR371) can predict relapse risk in early-stage germ cell malignancy under active surveillance, though the study authors emphasize that...

Replimune said it will resubmit its biologics license application for RP1, its melanoma therapy, shortly after prior FDA rejections in July 2025 and April. The company linked the timing to...

A healthcare and life sciences IPO market update says biotech dealmaking and listing activity is strengthening in 2026, but investors continue to demand high-quality data and differentiated...

Revolution Medicines’ daraxonrasib posted detailed, phase 3 results at ASCO that investigators described as practice-changing in metastatic RAS G12-mutant pancreatic cancer. In the trial...

Akeso’s ivonescimab delivered a 34% overall survival improvement in an interim analysis of the China-based phase 3 Harmoni-6 trial, presented at ASCO. In previously untreated advanced squamous...